Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)
|
6 Months Ended |
Mar. 31, 2026 |
|---|
| Restatement of Previously Issued Unaudited Condensed Financial Statements [Abstract] |
|
| Schedule of Condensed Balance Sheet |
Condensed Balance Sheet as of March
31, 2026 (Excerpt)
| | |
As Previously | | |
| | |
| |
| | |
Reported | | |
Adjustment | | |
As Restated | |
| Accounts receivable | |
$ | 2,426,518 | | |
$ | (529,135 | ) | |
$ | 1,897,383 | |
| Inventory, net | |
$ | 1,866,633 | | |
$ | 232,782 | | |
$ | 2,099,415 | |
| Total current assets | |
$ | 7,403,798 | | |
$ | (296,353 | ) | |
$ | 7,107,445 | |
| Total assets | |
$ | 7,864,958 | | |
$ | (296,353 | ) | |
$ | 7,568,605 | |
| Accumulated deficit | |
$ | (82,133,346 | ) | |
$ | (296,353 | ) | |
$ | (82,429,699 | ) |
| Total stockholders’ equity | |
$ | 5,373,636 | | |
$ | (296,353 | ) | |
$ | 5,077,283 | |
| Total liabilities and stockholders’ equity | |
$ | 7,864,958 | | |
$ | (296,353 | ) | |
$ | 7,568,605 | |
|
| Schedule of Condensed Statement of Operations |
Condensed Statement of Operations -
Three Months Ended March 31, 2026 (Excerpt)
| | |
As Previously | | |
| | |
| |
| | |
Reported | | |
Adjustment | | |
As Restated | |
| Product revenue | |
$ | 2,391,185 | | |
$ | (529,135 | ) | |
$ | 1,862,050 | |
| Cost of product revenue | |
$ | 1,104,568 | | |
$ | (232,782 | ) | |
$ | 871,786 | |
| Product gross profit | |
$ | 1,286,617 | | |
$ | (296,353 | ) | |
$ | 990,264 | |
| Loss from operations | |
$ | (2,100,844 | ) | |
$ | (296,353 | ) | |
$ | (2,397,197 | ) |
| Loss before income taxes | |
$ | (2,085,669 | ) | |
$ | (296,353 | ) | |
$ | (2,382,022 | ) |
| Net loss | |
$ | (2,085,669 | ) | |
$ | (296,353 | ) | |
$ | (2,382,022 | ) |
| Net loss per share, basic and diluted | |
$ | (0.25 | ) | |
$ | (0.03 | ) | |
$ | (0.28 | ) |
Condensed Statement of Operations -
Six Months Ended March 31, 2026 (Excerpt)
| | |
As Previously | | |
| | |
| |
| | |
Reported | | |
Adjustment | | |
As Restated | |
| Product revenue | |
$ | 5,283,820 | | |
$ | (529,135 | ) | |
$ | 4,754,685 | |
| Cost of product revenue | |
$ | 2,429,375 | | |
$ | (232,782 | ) | |
$ | 2,196,593 | |
| Product gross profit | |
$ | 2,854,445 | | |
$ | (296,353 | ) | |
$ | 2,558,092 | |
| Loss from operations | |
$ | (3,808,151 | ) | |
$ | (296,353 | ) | |
$ | (4,104,504 | ) |
| Loss before income taxes | |
$ | (3,523,559 | ) | |
$ | (296,353 | ) | |
$ | (3,819,912 | ) |
| Net loss | |
$ | (3,523,559 | ) | |
$ | (296,353 | ) | |
$ | (3,819,912 | ) |
| Net loss per share, basic | |
$ | (0.42 | ) | |
$ | (0.03 | ) | |
$ | (0.45 | ) |
| Net loss per share, diluted | |
$ | (0.44 | ) | |
$ | (0.03 | ) | |
$ | (0.47 | ) |
|
| Schedule of Condensed Statement of Stockholders’ Equity |
Condensed Statement of Stockholders’
Equity - Three Months Ended March 31, 2026 (Excerpt)
| | |
As Previously | | |
| | |
| |
| | |
Reported | | |
Adjustment | | |
As Restated | |
| Net loss | |
$ | (2,085,669 | ) | |
$ | (296,353 | ) | |
$ | (2,382,022 | ) |
| Accumulated deficit | |
$ | (82,133,346 | ) | |
$ | (296,353 | ) | |
$ | (82,429,699 | ) |
| Total stockholders’ equity | |
$ | 5,373,636 | | |
$ | (296,353 | ) | |
$ | 5,077,283 | |
|
| Schedule of Condensed Statement of Cash Flows |
Condensed Statement of Cash Flows -
Six Months Ended March 31, 2026 (Excerpt)
| | |
As Previously | | |
| | |
| |
| | |
Reported | | |
Adjustment | | |
As Restated | |
| Net loss | |
$ | (3,523,559 | ) | |
$ | (296,353 | ) | |
$ | (3,819,912 | ) |
| Accounts receivable | |
$ | (1,161,713 | ) | |
$ | 529,135 | | |
$ | (632,578 | ) |
| Inventory | |
$ | 360,172 | | |
$ | (232,782 | ) | |
$ | 127,390 | |
| Net cash used in operating activities | |
$ | (4,444,546 | ) | |
$ | - | | |
$ | (4,444,546 | ) |
|